Report Code: A02373 | Nov 2023 | Pages: NA | ||
Tables: NA | Charts: NA |
|
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Non-invasive Prenatal Testing (nipt) Market
Request Now !Non-invasive prenatal testing is also known as non-invasive parenteral screening, which is a nascent genetic process of examining a fetal cell free DNA present in the mothers blood serum for detecting common fetal aneuploidies. Its main objective is early detection of genetic disorders such as trisomy 21 (Down syndrome), trisomy 18 (Edward syndrome), trisomy 13 (Patau syndrome), and monosomy X (Turner syndrome). It can also detect the blood group and rhesus actor of the fetus. Some of the NIPTs currently available in the global market are MaterniT21 PLUS, Harmony, Panorama, NIFTY, PrenaTest, BambniTest, and others.
Growth in reimbursements for the NIPT sector, increased shift from invasive methods to non-invasive methods, and growth of maternal age (associated with growth in the risk of chromosomal abnormalities in babies) drive the market. In addition, launch and development of advanced and new technologies and non-invasive parenteral testing products also fuels the market growth. However, lack of skilled professionals as well as strict regulatory guidelines and ethical hurdles slow down the process of approvals and marketing, thus restricting the market growth. Untapped emergence of new market in Asia-Pacific make way for growth opportunities for his market.
The report segments the market on the basis of product, method, application, end users, and region. Based on product, it is bifurcated into consumables and instruments. Based on method, it is divided into ultrasound detection, biochemical screening tests, cell-free DNA in maternal plasma tests, and fetal cells in maternal blood tests. Based on application, it can be categorized into trisomy, microdeletion syndrome, and other applications. By geography, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.
The key players of non-invasive parenteral testing market are Ge Healthcare (General Electric Company), Koninklijke Philips N.V., Illumina, Inc., Thermo Fisher Scientific, Inc., F. Hoffman-La Roche Ltd., Pacific Biosciences of California, Inc., Perkinelmer, Inc., Qiagen N.V., Agilent Technologies, Inc., and Beijing Genomics Institute.
Key Benefits
Non-Invasive Prenatal Testing (NIPT) Market Report Highlights
Aspects | Details |
---|---|
By Product |
|
By Method |
|
By Application |
|
By End User |
|
By Region |
|
Key Market Players | GE Healthcare (General Electric Company), Agilent Technologies, Inc., Illumina, Inc., Perkinelmer, Inc., Koninklijke Philips N.V., F. Hoffman-La Roche Ltd., Beijing Genomics Institute, Thermo Fisher Scientific, Inc., Pacific Biosciences of California, Inc., Qiagen N.V. |
Start reading.
This Report and over 66,965+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers